ARAlejandro Rodríguez-Ruiz

Alejandro Rodríguez-Ruiz

*This is an algorithmically generated author record based on publicly available information.

Alejandro Rodríguez-Ruiz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial

    by Esperanza Elías-Cabot, Sara Romero-Martín, José Luis Raya-Povedano, Alejandro Rodríguez-Ruiz, Marina Álvarez-Benito

    Artificial intelligence (AI) systems have been demonstrated to improve the accuracy of screening mammograms. Here this prospective, paired, noninferiority clinical trial evaluated whether AI could safely reduce workload by excluding low-risk exams from radiologist reading. Between March 2022 and January 2024, 31,301 women were included in the trial and underwent routine mammograms. Two reading strategies were applied in parallel: standard double-blind reading and partially autonomous AI-supported screening, where cases classified by AI as low risk were assessed as normal and the rest were double read with AI support. The primary outcomes were radiologist workload, cancer detection rate and recall rate. In the AI strategy, radiologist workload was 63.6% lower; the cancer detection rate was 15.2% higher (95% confidence interval 6.6%, 24.4%), increasing from 6.3 of 1,000 to 7.3 of 1,000, P < 0.001; and the recall rate was not noninferior and was 14.8% higher (95% confidence interval 9.0%, 20.6%). Subanalyses by modality highlighted a similar workload reduction in digital mammography (−62.1%) and digital breast tomosynthesis (−65.5%). However, in digital mammography, the cancer detection rate increased by 1.6 of 1,000 and the recall rate by 1.3%, while both remained stable in digital breast tomosynthesis. These results demonstrate the feasibility of a partially automated AI workflow in breast cancer screening, avoiding human reading of studies classified as low risk. ClinicalTrials.gov: NCT04849776.


  • Open Access

    An Exploration of Discrepant Recalls Between AI and Human Readers of Malignant Lesions in Digital Mammography Screening

    by Suzanne L. van Winkel, Ioannis Sechopoulos, Alejandro Rodríguez-Ruiz, Wouter J. H. Veldkamp, Gisella Gennaro, Margarita Chevalier, Thomas H. Helbich, Tianyu Zhang, Matthew G. Wallis, Ritse M. Mann

    Background: The integration of artificial intelligence (AI) in digital mammography (DM) screening holds promise for early breast cancer detection, potentially enhancing accuracy and efficiency. However, AI performance is not identical to that of human observers. We aimed to identify common morphological image characteristics of true cancers that are missed by either AI or human screening when their interpretations are discrepant. Methods: Twenty-six breast cancer-positive cases, identified from a large retrospective multi-institutional digital mammography dataset based on discrepant AI and human interpretations, were included in a reader study. Ground truth was confirmed by histopathology or ≥1-year follow-up. Fourteen radiologists assessed lesion visibility, morphological features, and likelihood of malignancy. AI performance was evaluated using receiver operating characteristic (ROC) analysis and area under the curve (AUC). The reader study results were analyzed using interobserver agreement measures and descriptive statistics. Results: AI demonstrated high discriminative capability in the full dataset, with AUCs ranging from 0.903 (95% CI: 0.862–0.944) to 0.946 (95% CI: 0.896–0.996). Cancers missed by AI had a significantly smaller median size (9.0 mm, IQR 6.5–12.0) compared to those missed by human readers (21.0 mm, IQR 10.5–41.0) (p = 0.0014). Cancers in discrepant cases were often described as having ‘low visibility’, ‘indistinct margins’, or ‘irregular shape’. Calcifications were observed in 27% of human-missed cancers (42/154) versus 18% of AI-missed cancers (38/210). A very high likelihood of malignancy was assigned in 32.5% (50/154) of human-missed cancers compared to 19.5% (41/210) of AI-missed cancers. Overall inter-rater agreement was poor to fair (p = 0.396). Furthermore, 50/154 (32.5%) human-missed cancers were deemed to have a very high likelihood of malignancy, compared to 41/210 (19.5%) AI-missed cancers (p = 0.8). Overall inter-rater agreement on the items assessed during the reader study was poor to fair (<0.40), suggesting that interpretation of the selected images was challenging. Conclusions: Lesions missed by AI were smaller and less often calcified than cancers missed by human readers. Cancers missed by AI tended to show lower levels of suspicion than those missed by human readers. While definitive conclusions are premature, the findings highlight the complementary roles of AI and human readers in mammographic interpretation.